Clinical Trial Update: This is a Study to Determine the Antidepressant Effects of AZD6765 [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated the antidepressant effects of AZD6765 in individuals with treatment-resistant major depressive disorder; results were posted after the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder
• Treatment-resistant Major Depressive Disorder

Drugs mentioned

• AZD6765 (lanicemine)

Snippet

Sponsor: AstraZeneca | Conditions: Treatment Resistant Major Depressive Disorder | Phase 2 | Status: COMPLETED | Results posted: 2014-10-21